MeiraGTx Stock Earnings Estimates Reduced by HC Wainwright

MeiraGTx Holdings PLC (NASDAQ:MGTX – Free Report) – Equities research analysts at HC Wainwright reduced their FY2026 EPS estimates for MeiraGTx in a research note issued to investors on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of $0.10 for the year, down from their previous estimate of $0.36. The consensus estimate for MeiraGTx’s current full-year earnings is $0.32 per share. HC Wainwright also issued estimates for MeiraGTx’s Q4 2026 earnings at ($0.55) EPS, Q1 2027 earnings at ($0.53) EPS, Q2 2027 earnings at ($0.56) EPS, Q3 2027 earnings at ($0.57) EPS, Q4 2027 earnings at ($0.18) EPS and FY2027 earnings at ($1.83) EPS.

MeiraGTx (NASDAQ:MGTX – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.03). The company had revenue of $4.81 million for the quarter, compared to analysts’ expectations of $6.95 million. MeiraGTx had a net margin of 19.46% and a return on equity of 154.51%.

A number of other research analysts also recently weighed in on the company. Royal Bank Of Canada increased their target price on MeiraGTx from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Friday, August 14th. The Goldman Sachs Group assumed coverage on MeiraGTx in a research note on Thursday, September 24th. They set a “neutral” rating and a $16.00 price target for the company. Wall Street Zen lowered shares of MeiraGTx from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings cut shares of MeiraGTx from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday. Finally, Zacks Research cut shares of MeiraGTx from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 11th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, MeiraGTx presently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Get Our Latest Report on MGTX

MeiraGTx Stock Performance

MGTX stock opened at $8.74 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.76 and a quick ratio of 3.76. MeiraGTx has a 1 year low of $6.62 and a 1 year high of $15.35. The company has a market cap of $839.39 million, a P/E ratio of 10.92 and a beta of 1.09. The stock’s fifty day moving average price is $10.61 and its 200-day moving average price is $10.37.

Insiders Place Their Bets

In related news, insider Stuart Naylor sold 27,659 shares of the firm’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $10.64, for a total value of $294,291.76. Following the transaction, the insider directly owned 613,187 shares of the company’s stock, valued at approximately $6,524,309.68. This trade represents a 4.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Richard Giroux sold 56,000 shares of MeiraGTx stock in a transaction on Tuesday, October 20th. The shares were sold at an average price of $9.95, for a total value of $557,200.00. Following the transaction, the chief financial officer owned 852,530 shares in the company, valued at $8,482,673.50. This trade represents a 6.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.40% of the company’s stock.

Institutional Trading of MeiraGTx

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Johnson & Johnson purchased a new stake in MeiraGTx in the 2nd quarter worth $89,720,775. BlackRock Inc. purchased a new position in shares of MeiraGTx in the second quarter valued at about $64,269,000. Opaleye Management Inc. lifted its position in shares of MeiraGTx by 67.2% in the second quarter. Opaleye Management Inc. now owns 3,550,000 shares of the company’s stock valued at $47,960,000 after acquiring an additional 1,426,741 shares in the last quarter. Rubric Capital Management LP lifted its position in shares of MeiraGTx by 13.4% in the first quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock valued at $60,620,000 after acquiring an additional 824,669 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of MeiraGTx by 250.3% in the third quarter. Goldman Sachs Group Inc. now owns 1,147,015 shares of the company’s stock worth $12,617,000 after acquiring an additional 819,599 shares during the period. Hedge funds and other institutional investors own 67.48% of the company’s stock.

MeiraGTx Company Profile

(Get Free Report)

MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.

See Also

Earnings History and Estimates for MeiraGTx (NASDAQ:MGTX)

Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.